No CrossRef data available.
Article contents
544 – FDA Approved Psychotrop IC Medication S Listing for Common Psychiatri C Illnesses in Current us Pacific Military Medicine and Comparison with Europe
Published online by Cambridge University Press: 15 April 2020
Abstract
What are the FDA and EMEA approved Psychotropic Medications for Psychiatric Illnesses? What do these approval processes mean?
Describe the process for FDA/ EMEA approval of drugs used to treat psychiatric disordres, identify disorders of DSM-IV TR commonly seen in Medicine, present currently FDA/EMEA approved Psychotropic Medications for Psychiatric Illnesses in International Medicine.
To identify psychiatric disorders of DSM-IV TR commonly seen in Medicine and have access to a FDA/EMEA approved Psychotropic Medications.
The FDA and its European Counterpart, the EMEA are recognized for enforcing two of the world's most rigorous review processes, determining what medications are safe/effective, which makes their approval a meaningful title to patients. A readily accessible list of DSM-IV TR Psychiatric disorders with the corresponding FDA and EMEA approved medications listed would help communication between providers and patients and prevent bad outcomes. Currently, no such document is readily available.
Review of most commonly seen psychiatric disorders in International Medicine. Review of the current FDA Orange book for current FDA approved Psychotrop Medications for Common Psychiatric Illnesses.
A list of DSM-IV TR Psychiatric disorders commonly seen in Medicine with the corresponding FDA/EMEA approved medications listed.
To create a user friendly document listing common DSM-IV TR Psychiatric disorders seen in the US military setting with the corresponding FDA approved psychotropic medications to aid healthcare providers, and educate patients about the significance of using a medication for its FDA approved diagnoses versus “off-label” prescribing, and to compare this process to the EMEA process.
- Type
- Abstract
- Information
- European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E125
- Copyright
- Copyright © European Psychiatric Association 2013
Comments
No Comments have been published for this article.